Research effects
PT-141 (Bremelanotide) is a synthetic cyclic peptide and melanocortin receptor (MC1R, MC4R) agonist. Its core mechanism involves activating MC4R in the central nervous system to modulate the hypothalamic-pituitary-gonadal axis, enhancing endogenous sexual desire and response pathways, while peripheral MC1R activation can induce penile or clitoral erection. Unlike PDE5 inhibitors that act solely on vasculature, PT-141 acts centrally, offering unique therapeutic value for neurogenic or psychogenic sexual dysfunction. It is FDA-approved for hypoactive sexual desire disorder in premenopausal women but used off-label for male erectile dysfunction. Common adverse effects include nausea, flushing, headache, and injection-site reactions; blood pressure fluctuations require monitoring. Long-term safety data remain limited, necessitating physician supervision.
